← Back to Search

Behavioural Intervention

Guided ADHD Therapy for ADHD (GAMES Trial)

N/A
Waitlist Available
Led By Ann Childress, MD
Research Sponsored by Lumos Labs, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Confirmed ADHD diagnosis, combined or inattentive type, at Screening based on DSM-5 criteria and established via the MINI-Adult, administered by a trained clinician
Subjects 22-55 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at study day 63
Awards & highlights

GAMES Trial Summary

This trial will test a new digital therapy for treating adults with ADHD. The therapy will be delivered through a game, and the goal is to see if it is safe and effective.

Who is the study for?
Adults aged 22-55 with ADHD, an IQ score of at least 80, and a clinician-rated ADHD-RS total score ≥28 can join. They must speak English, not be on certain ADHD medications or agree to stop them if they are, and have daily access to a wireless network. People with severe psychiatric disorders, recent substance abuse, motor conditions that prevent game playing, or who've used similar digital therapies recently cannot participate.Check my eligibility
What is being tested?
The trial is testing the safety and effectiveness of a new at-home digital therapy for adults with ADHD. It's game-based and compared against a control therapy. Participants will use this intervention in their own environment to see if it helps manage their symptoms better than existing methods.See study design
What are the potential side effects?
Since this is a non-pharmacological treatment involving digital games for managing ADHD symptoms, side effects might include discomfort like headaches or dizziness from screen time but are expected to be minimal compared to medication-related side effects.

GAMES Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with ADHD, either combined or inattentive type, by a trained clinician.
Select...
I am between 22 and 55 years old.

GAMES Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at study day 63
This trial's timeline: 3 weeks for screening, Varies for treatment, and at study day 63 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Test of Variables of Attention (TOVA®) Attention Comparison Score (ACS)
Secondary outcome measures
ADHD-RS-5 Inattention Subscale with Adult Prompts
Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Working Memory and Inhibit Percentiles
Cambridge Brain Sciences Spatial Span
+3 more

GAMES Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ADHD TherapyExperimental Treatment1 Intervention
Group II: Control TherapyActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ADHD Therapy
2022
N/A
~560

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for ADHD include stimulant medications (e.g., methylphenidate and amphetamines), non-stimulant medications (e.g., atomoxetine), and behavioral therapies. Stimulant medications work by increasing the levels of dopamine and norepinephrine in the brain, which helps improve attention and reduce hyperactivity and impulsivity. Non-stimulant medications, like atomoxetine, selectively inhibit the reuptake of norepinephrine, enhancing attention and impulse control. Behavioral therapies, such as cognitive-behavioral therapy (CBT) and mindfulness-based cognitive therapy (MBCT), focus on developing coping strategies and improving executive function. Game-based digital therapies engage patients through interactive game mechanics to improve attention and reduce hyperactivity/impulsivity by providing a structured and stimulating environment that encourages focus and self-regulation. These treatments are crucial for ADHD patients as they address core symptoms, improve daily functioning, and enhance overall quality of life.
Serious Video Games: Angels or Demons in Patients With Attention-Deficit Hyperactivity Disorder? A Quasi-Systematic Review.

Find a Location

Who is running the clinical trial?

Lumos Labs, Inc.Lead Sponsor
14 Previous Clinical Trials
15,676 Total Patients Enrolled
1 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
194 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Ann Childress, MDPrincipal InvestigatorClinical Research of Southern Nevada, LLC
11 Previous Clinical Trials
1,275 Total Patients Enrolled
10 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
1,263 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)

Media Library

ADHD Therapy (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05296473 — N/A
Attention Deficit Hyperactivity Disorder (ADHD) Research Study Groups: ADHD Therapy, Control Therapy
Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trial 2023: ADHD Therapy Highlights & Side Effects. Trial Name: NCT05296473 — N/A
ADHD Therapy (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05296473 — N/A
Attention Deficit Hyperactivity Disorder (ADHD) Patient Testimony for trial: Trial Name: NCT05296473 — N/A
~187 spots leftby Jun 2025